Anyone doing a clinical trial of a drug is supposed to announce publicly that the trial is under way and describe its goals. But David Moher of the Ottawa Hospital Research Institute said many tests are conducted without this disclosure.

This allows scientists, or the drug companies who pay for the work, to release good results but quietly cancel anything that looks bad for their product.

"Selective outcome [result] reporting is prevalent," Dr. Moher's study concluded.